Oral graft vs. host disease in children - Treatment with topical tacrolimus ointment

Pediatric Transplantation

Volumn 11, Issue 3, 2007, Pages 306-309

  Albert, Michael H ^a   Becker, B ^a   Schuster, F R ^a   Klein, B ^a   Binder, V ^a   Adam, K ^a   Nienhoff, C ^a   Fuhrer M ^a   Borkhardt, A ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Oral graft vs. host disease; Pediatric; Tacrolimus

Indexed keywords

AMSACRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; METHOTREXATE; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BURNING MOUTH SYNDROME; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FEMALE; FOLLOW UP; FOOD INTAKE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MOUTH DISCOMFORT; MYELOABLATIVE CONDITIONING; ORAL GRAFT VERSUS HOST DISEASE; PILOT STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34147145909     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00666.x     Document Type: Article

References (28)

1. SALE GE, SHULMAN HM, SCHUBERT MM, et al. Oral and ophthalmic pathology of graft versus host disease in man: Predictive value of the lip biopsy. Hum Pathol 1981: 12: 1022-1030.
2. PAVLETIC SZ, SMITH LM, BISHOP MR, et al. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stemcell transplantation. Am J Hematol 2005: 78: 265-274.
3. IMANGULI MM, PAVLETIC SZ, GUADAGNINI JP, BRAHIM JS, ATKINSON JC. Chronic graft versus host disease of oral mucosa: Review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006: 101: 175-183.
4. SCHUBERT MM, SULLIVAN KM, MORTON TH, et al. Oral manifestations of chronic graft-v-host disease. Arch Intern Med 1984: 144: 1591-1595.
5. FILIPOVICH AH, WEISDORF D, PAVLETIC S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005: 11: 945-956.
6. LENSSEN P, SHERRY ME, CHENEY CL, et al. Prevalence of nutrition-related problems among long-term survivors of allogeneic marrow transplantation. J Am Diet Assoc 1990: 90: 835-842.
7. TREISTER NS, WOO SB, O'HOLLERAN EW, LEHMANN LE, PARSONS SK, GUINAN EC. Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005: 11: 721-731.
8. PLOSKER GL, FOSTER RH. Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000: 59: 323-389.
9. RATANATHARATHORN V, NASH RA, PRZEPIORKA D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998: 92: 2303-2314.
10. NASH RA, ANTIN JH, KARANES C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000: 96: 2062-2068.
11. KANAMARU A, TAKEMOTO Y, KAKISHITA E, et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transplant 1995: 15: 885-889.
12. ASHCROFT DM, DIMMOCK P, GARSIDE R, STEIN K, WILLIAMS HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: Meta-analysis of randomised controlled trials. BMJ 2005: 330: 516.
13. REITAMO S, WOLLENBERG A, SCHOPF E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000: 136: 999-1006.
14. CHOI CJ, NGHIEM P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: A case series of 18 patients. Arch Dermatol 2001: 137: 1202-1206.
15. ELAD S, OR R, RESNICK I, SHAPIRA MY. Topical tacrolimus - A novel treatment alternative for cutaneous chronic graft-versus-host disease. Transpl Int 2003: 16: 665-670.
16. HODGSON TA, SAHNI N, KALIAKATSOU F, BUCHANAN JA, PORTER SR. Long-term efficacy and safety of topical tacrolimus in the management of ulcerative/erosive oral lichen planus. Eur J Dermatol 2003: 13: 466-470.
17. ECKARDT A, STARKE O, STADLER M, REUTER C, HERTENSTEIN B. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: Highly effective treatment with topical tacrolimus. Oral Oncol 2004: 40: 811-814.
18. SANCHEZ AR, SHERIDAN PJ, ROGERS RS. Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: A case report. J Periodontol 2004: 75: 613-619.
19. ELAD S, OR R, GARFUNKEL AA, SHAPIRA MY. Budesonide: A novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003: 95: 308-311.
20. 2 laser in oral graft-versus-host disease: A pilot study. Bone Marrow Transplant 2003: 32: 1031-1034.
21. WOLFF D, ANDERS V, CORIO R, et al. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graftvs.-host disease. Photodermatol Photoimmunol Photomed 2004: 20: 184-190.
22. EPSTEIN JB, NANTEL S, SHEOLTCH SM. Topical azathioprine in the combined treatment of chronic oral graft-versus-host disease. Bone Marrow Transplant 2000: 25: 683-687.
23. REDDING SW, CALLANDER NS, HAVEMAN CW, LEONARD DL. Treatment of oral chronic graft-versus-host disease with PUVA therapy: Case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998: 86: 183-187.
24. Astellas Pharma GmbH. Prescribing Information "Prograf Hartkapseln" (German). Munich: Astellas Pharma GmbH, 2006.
25. FDA Public Health Advisory. Elidel (Pimecrolimus) Cream and Protopic (Tacrolimus) Ointment. Available at http://www.fda.gov/cder/drug/advisory/ elidel_protopic.htm. Accessed November 27, 2006.
26. BECKER JC, HOUBEN R, VETTER CS, BROCKER EB. The carcinogenic potential of tacrolimus ointment beyond immune suppression: A hypothesis creating case report. BMC Cancer 2006: 6: 7.
27. LEISENRING W, FRIEDMAN DL, FLOWERS ME, SCHWARTZ JL, DEEG HJ. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006: 24: 1119-1126.
28. PAVLETIC SZ, MARTIN P, LEE SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006: 12: 252-266.